1
|
Lyu Y, Choong A, Chow EPF, Seib KL, Marshall HS, Unemo M, de Voux A, Wang B, Miranda AE, Gottlieb SL, Mello MB, Wi T, Baggaley R, Marshall C, Abu-Raddad LJ, Abara WE, Chen XS, Ong JJ. Vaccine value profile for Neisseria gonorrhoeae. Vaccine 2024; 42:S42-S69. [PMID: 38123397 PMCID: PMC11169088 DOI: 10.1016/j.vaccine.2023.01.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2022] [Revised: 12/23/2022] [Accepted: 01/23/2023] [Indexed: 12/23/2023]
Abstract
Neisseria gonorrhoeae infection (gonorrhoea) is a global public health challenge, causing substantial sexual and reproductive health consequences, such as infertility, pregnancy complications and increased acquisition or transmission of HIV. There is an urgency to controlling gonorrhoea because of increasing antimicrobial resistance to ceftriaxone, the last remaining treatment option, and the potential for gonorrhoea to become untreatable. No licensed gonococcal vaccine is available. Mounting observational evidence suggests that N. meningitidis serogroup B outer membrane vesicle-based vaccines may induce cross-protection against N. gonorrhoeae (estimated 30%-40% effectiveness using the 4CMenB vaccine). Clinical trials to determine the efficacy of the 4CMenB vaccine against N. gonorrhoeae are underway, as are Phase 1/2 studies of a new gonococcal-specific vaccine candidate. Ultimately, a gonococcal vaccine must be accessible, affordable and equitably dispensed, given that those most affected by gonorrhoea are also those who may be most disadvantaged in our societies, and most cases are in less-resourced settings. This vaccine value profile (VVP) provides a high level, holistic assessment of the current data to inform the potential public health, economic and societal value of pipeline vaccines. This was developed by a working group of subject matter experts from academia, non-profit organizations, public private partnerships and multi-lateral organizations. All contributors have extensive expertise on various elements of the N. gonorrhoeae VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using published data obtained from peer-reviewed journals or reports.
Collapse
Affiliation(s)
- Yiming Lyu
- University of Melbourne, Parkville, Victoria 3010, Australia.
| | - Annabelle Choong
- Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, 99 Commercial Road, Melbourne, Victoria 3004, Australia.
| | - Eric P F Chow
- Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, 99 Commercial Road, Melbourne, Victoria 3004, Australia; Melbourne Sexual Health Centre, Alfred Health, 580 Swanston Street, Melbourne, Victoria 3053, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, 207 Bouverie Street, Melbourne, Victoria 3053, Australia.
| | - Kate L Seib
- Institute for Glycomics, Griffith University, Gold Coast, Queensland 4222, Australia.
| | - Helen S Marshall
- The University of Adelaide, Adelaide, South Australia 5005, Australia; Women's and Children's Health Network, North Adelaide, South Australia, Australia.
| | - Magnus Unemo
- WHO CC for Gonorrhoea and Other STIs, Örebro University, Örebro, Sweden; Institute for Global Health, University College London (UCL), London, UK.
| | - Alex de Voux
- Division of Epidemiology and Biostatistics, Faculty of Health Sciences, University of Cape Town, Rondebosch, Cape Town 7700, South Africa.
| | - Bing Wang
- The University of Adelaide, Adelaide, South Australia 5005, Australia; Women's and Children's Health Network, North Adelaide, South Australia, Australia.
| | - Angelica E Miranda
- Department of Social Medicine, Universidade Federal do Espirito Santo, Av. Fernando Ferrari, 514 - Goiabeiras, Vitória - ES 29075-910, Brazil.
| | - Sami L Gottlieb
- Department of Sexual and Reproductive Health and Research, World Health Organization, Av. Appia 20, 1211 Genève, Switzerland.
| | - Maeve B Mello
- Global HIV, Hepatitis and STI Programmes, World Health Organization, Av. Appia 20, 1211 Genève, Switzerland.
| | - Teodora Wi
- Global HIV, Hepatitis and STI Programmes, World Health Organization, Av. Appia 20, 1211 Genève, Switzerland.
| | - Rachel Baggaley
- Global HIV, Hepatitis and STI Programmes, World Health Organization, Av. Appia 20, 1211 Genève, Switzerland.
| | - Caroline Marshall
- Department of Immunization, Vaccines and Biologicals, World Health Organization, Av. Appia 20, 1211 Genève, Switzerland.
| | - Laith J Abu-Raddad
- Weill Cornell Medicine-Qatar, Qatar Foundation - Education City, Box 24144, Doha, Qatar.
| | - Winston E Abara
- Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30329, USA.
| | - Xiang-Sheng Chen
- National Center for STD Control of China CDC, 12 Jiangwangmiao Street, Nanjing 210042, China.
| | - Jason J Ong
- Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, 99 Commercial Road, Melbourne, Victoria 3004, Australia.
| |
Collapse
|
2
|
Haber LA, Wurcel AG, Berk J. Measles in jails and prisons. Lancet Public Health 2024; 9:e280. [PMID: 38614107 DOI: 10.1016/s2468-2667(24)00074-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2024] [Accepted: 04/03/2024] [Indexed: 04/15/2024]
Affiliation(s)
| | | | - Justin Berk
- Alpert Medical School at Brown University, Providence, RI, USA
| |
Collapse
|
3
|
Mazzilli S, Cocco N, Petri D, Moazen B, Rosello A, D'Arcy J, Plugge E, Baglietto L, Murauer E, Stöver H, Trattonikolas T, Stylianou I, Doltu S, Busmachiu V, Mavrou J, Yiasemi I, Barbiros I, da Costa FA, Meroueh F, Ranieri R, Tavoschi L. Implementation of COVID-19 vaccination services in prison in six European countries: translating emergency intervention into routine life-course vaccination. BMC Public Health 2024; 24:1001. [PMID: 38600540 PMCID: PMC11007954 DOI: 10.1186/s12889-024-18063-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2023] [Accepted: 02/10/2024] [Indexed: 04/12/2024] Open
Abstract
BACKGROUND Evidence has shown that the risk of transmission of SARS-CoV-2 is much higher in prisons than in the community. The release of the COVID-19 vaccine and the recommendation by WHO to include prisons among priority settings have led to the inclusion of prisons in national COVID-19 vaccination strategies. Evidence on prison health and healthcare services provision is limited and often focuses on a single country or institution due to the multiple challenges of conducting research in prison settings. The present study was done in the framework of the EU-founded project RISE-Vac. It aimed to analyse the best practices and challenges applied in implementing COVID-19 universal vaccination services during the pandemic to support future expansion of routine life course vaccination services for people living in prison (PLP). METHODS Two online cross-sectional surveys were designed and piloted: survey1 on prison characteristics and (non-COVID-19) immunisation practices; survey2 on the implementation and coverage of COVID-19 vaccination with open-ended questions for thematic analysis. Each RISE-Vac project partner distributed the questionnaire to one or two prisons in their country. Answers were collected from eight European prisons' directors or medical directors between November 2021-May 2022. RESULTS According to our findings, the implementation modalities of COVID-19 vaccination services in the surveyed prisons were effective in improving PLP vaccination coverage. Strategies for optimal management of the vaccination campaign included: periodic time slot for PLP vaccination; new staff recruitment and task shifting; distribution of informational material both to PLP and prison staff. Key challenges included continuity of care after release, immunisation information system, and vaccine hesitancy. CONCLUSIONS To the best of our knowledge, this is the first study describing the implementation of COVID-19 vaccination services in European prisons, suggesting that the expansion of vaccination provision in prison is possible. There is no unique solution that will fit every country but commonalities likely to be important in the design and implementation of future vaccination campaigns targeting PLP emerged. Increased availability of vaccination services in prison is not only possible, but feasible and highly desirable, and can contribute to the reduction of health inequalities.
Collapse
Affiliation(s)
- Sara Mazzilli
- Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
- Scuola Normale Superiore, Pisa, Italy
| | - Nicola Cocco
- Infectious Diseases Service, Penitentiary Health System, Azienda Socio-Sanitaria Territoriale Santi Paolo e Carlo, Milan, Italy
| | - Davide Petri
- Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
| | - Babak Moazen
- Department of Health and Social Work, Institute of Addiction Research (ISFF), Frankfurt University of Applied Sciences, Frankfurt/Main, Germany
- Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Federal Republic of Germany
| | | | | | - Emma Plugge
- Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, UK
| | - Laura Baglietto
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Eva Murauer
- Health Unit of the Villeneuve-les-Maguelone prison, University Hospital Centre Montpellier, Montpellier, France
| | - Heino Stöver
- Department of Health and Social Work, Institute of Addiction Research (ISFF), Frankfurt University of Applied Sciences, Frankfurt/Main, Germany
| | - Tassos Trattonikolas
- Ministry of Justice and Public Order - Cyprus Prison Department, Nicosia, Cyprus
| | - Iakovos Stylianou
- Ministry of Justice and Public Order - Cyprus Prison Department, Nicosia, Cyprus
| | | | | | | | | | - Irina Barbiros
- National Administration of Penitentiaries, Chișinău, Republic of Moldova
| | | | - Fadi Meroueh
- Health Unit of the Villeneuve-les-Maguelone prison, University Hospital Centre Montpellier, Montpellier, France
| | - Roberto Ranieri
- Infectious Diseases Service, Penitentiary Health System, Azienda Socio-Sanitaria Territoriale Santi Paolo e Carlo, Milan, Italy
| | - Lara Tavoschi
- Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
| |
Collapse
|
4
|
Geremia N, Giovagnorio F, De Vito A, Martignago L, Fiore V, Rastrelli E, Madeddu G, Parisi SG, Starnini G, Panese S, Babudieri S. HBV in Italian Women's Jail: An Underestimated Problem? J Clin Med 2024; 13:1398. [PMID: 38592679 PMCID: PMC10932425 DOI: 10.3390/jcm13051398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2024] [Revised: 02/23/2024] [Accepted: 02/26/2024] [Indexed: 04/10/2024] Open
Abstract
BACKGROUND There is little information regarding the hepatitis B virus (HBV), vaccination status, and hepatitis B exposure in Italian women's jails. We aimed to describe the HBV exposure and HBs antibody (anti-HBs) protection levels in female prisoners. MATERIAL AND METHODS A retrospective multicentric study was performed in Italian prisons from 2021 to 2023. Univariate and multivariate analyses were conducted to identify risk factors for HBc antibody (anti-HBc) seropositivity and non-protective anti-HBs titer. RESULTS We included 156 patients. The median age was 41.0 (IQR 34.0-48.0). Of the studied subjects, 31 (19.9%) had anti-HBc positive titer. Two women were HBsAg positive. In the multivariate analysis, older age [OR 1.06 (CI 1.01-1.11), p = 0.011], North-Eastern European [OR 11.67 (3.29-41.30), p < 0.001] and African origin [OR 6.92 (CI 1.51-31.60), p = 0.013], and drug use [OR 6.55 (CI 1.96-21.9), p = 0.002] were risk factors for HBV exposure. Thirty-seven (32%) women had no history of HBV vaccination. Forty-four (38%) had an anti-HBs non-protective titer. In the multivariate analysis, North-Eastern European origin [OR 4.55 (CI 1.19-17.50), p = 0.027] was associated with unprotective anti-HBs titer. CONCLUSION Our results show both the low prevalence of HBV and protection in female prisoners. Age, North-Eastern European and African origin, and drug use have a role in exposure risk to HBV.
Collapse
Affiliation(s)
- Nicholas Geremia
- Unit of Infectious Diseases, Department of Clinical Medicine, Ospedale Dell'Angelo, 30174 Venice, Italy
- Unit of Infectious Diseases, Department of Clinical Medicine, Ospedale Civile "S.S. Giovanni e Paolo", 30122 Venice, Italy
| | | | - Andrea De Vito
- Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy
- School in Biomedical Science, Biomedical Science Department, University of Sassari, 07100 Sassari, Italy
| | - Luca Martignago
- Department of Molecular Medicine, University of Padua, 35121 Padua, Italy
| | - Vito Fiore
- Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy
| | - Elena Rastrelli
- Medicina Protetta-Unit of Infectious Diseases, Belcolle Hospital, 01100 Viterbo, Italy
| | - Giordano Madeddu
- Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy
| | | | - Giulio Starnini
- Medicina Protetta-Unit of Infectious Diseases, Belcolle Hospital, 01100 Viterbo, Italy
| | - Sandro Panese
- Unit of Infectious Diseases, Department of Clinical Medicine, Ospedale Dell'Angelo, 30174 Venice, Italy
- Unit of Infectious Diseases, Department of Clinical Medicine, Ospedale Civile "S.S. Giovanni e Paolo", 30122 Venice, Italy
| | - Sergio Babudieri
- Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy
| |
Collapse
|
5
|
Moazen B, Ismail N, Agbaria N, Mazzilli S, Petri D, Amaya A, D’Arcy J, Plugge E, Tavoschi L, Stöver H. Vaccination against emerging and reemerging infectious diseases in places of detention: a global multistage scoping review. Front Public Health 2024; 12:1323195. [PMID: 38347924 PMCID: PMC10859397 DOI: 10.3389/fpubh.2024.1323195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2023] [Accepted: 01/04/2024] [Indexed: 02/15/2024] Open
Abstract
Background Despite the elevated risks of infection transmission, people in prisons frequently encounter significant barriers in accessing essential healthcare services in many countries. The present scoping review aimed to evaluate the state of availability and model of delivery of vaccination services within correctional facilities across the globe. Methods Following the methodological framework for scoping reviews and adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension for scoping reviews criteria, we conducted a systematic search across four peer-reviewed literature databases (Medline via PubMed, Web of Science, the Cochrane Library, Science Direct, and EBSCO), as well as 14 sources of grey literature. Two researchers meticulously examined the identified papers independently to extract pertinent data published between 2012 and 2022. The quality of the selected publications was assessed using established quality assessment tools. Results Of the 11,281 identified papers 52 met the inclusion criteria. With the exception of one, all the included publications presented data from high-income countries, predominantly originating from the United States. Across the world, the most prevalent vaccines available in prison settings were COVID-19 and HBV vaccines, typically distributed in response to health crises such as pandemics, epidemics, and local outbreaks. Vaccine coverage and uptake rates within correctional facilities displayed noteworthy disparities among various countries and regions. Besides, individual and organizational barriers and facilitating factors of vaccination in prison settings emerged and discussed in the text. Discussion The lack of vaccination services combined with low rates of vaccination coverage and uptake among people living and working in correctional facilities represents a cause for concern. Prisons are not isolated from the broader community, therefore, efforts to increase vaccine uptake among people who live and work in prisons will yield broader public health benefits.
Collapse
Affiliation(s)
- Babak Moazen
- Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany
- Department of Health and Social Work, Institute of Addiction Research (ISFF), Frankfurt University of Applied Sciences, Frankfurt, Germany
| | - Nasrul Ismail
- School for Policy Studies, University of Bristol, Bristol, United Kingdom
| | - Nisreen Agbaria
- Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany
- Department of Health and Social Work, Institute of Addiction Research (ISFF), Frankfurt University of Applied Sciences, Frankfurt, Germany
| | - Sara Mazzilli
- Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
| | - Davide Petri
- Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
| | - Arianna Amaya
- Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany
| | | | - Emma Plugge
- UK Health Security Agency, London, United Kingdom
- Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
| | - Lara Tavoschi
- Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
| | - Heino Stöver
- Department of Health and Social Work, Institute of Addiction Research (ISFF), Frankfurt University of Applied Sciences, Frankfurt, Germany
| |
Collapse
|
6
|
Atem JN, El Ghaziri M. Enhancing Hepatitis A and B Vaccinations Through Electronic Clinical Decision Support Systems and Staff Education in a Correctional Facility. JOURNAL OF FORENSIC NURSING 2023; 19:253-261. [PMID: 36994992 DOI: 10.1097/jfn.0000000000000437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/19/2023]
Abstract
BACKGROUND Despite the prevalence and risks for hepatitis A virus (HAV) and hepatitis B virus (HBV) infection and the availability of safe and effective vaccines, HAV/HBV vaccinations are disproportionately low in jails. This quality improvement project evaluated the effectiveness of clinical decision support systems: electronic standing orders to nurses, clinical alerts to nurses and healthcare providers, and secondarily staff education in enhancing HAV and HBV vaccination and knowledge of hepatitis infection. METHODS We distributed a validated self-report hepatitis knowledge questionnaire (α = 0.7-0.8) before and after an educational presentation to nurses, nurse practitioners, and physicians ( N = 26) at a Northeastern state jail and then embedded electronic clinical alerts and standing orders in the electronic medical record. The questionnaire assessed pre- and posteducation knowledge scores. The number of vaccine status screenings and vaccinations was retrieved from the electronic medical record 3 months pre- and post-implementation. Descriptive statistics and the Wilcoxon signed-ranks test were used for data analysis. RESULTS Twenty-one participants completed the pretest, 18 attended the educational intervention, and 15 completed the posttest. Vaccine status screening increased by 97.5%, and HAV and HBV vaccinations increased by 8.7%. Knowledge scores improved significantly post-intervention ( p = 0.04), with an effect size of r = 0.67). DISCUSSION/CONCLUSION Using the Donabedian quality of care model, we showed that quality initiatives are feasible in a jail setting. Implementing a clinical decision support system and education improved the vaccination rate, which may decrease HAV/HBV incidence in the jail and prevent community spread.
Collapse
Affiliation(s)
- Jude N Atem
- Author Affiliation: Solomont School of Nursing, University of Massachusetts Lowell
| | | |
Collapse
|
7
|
Vicente-Alcalde N, Sferle SM, Franco-Paredes C, Tuells J. Acceptance of the COVID-19 Vaccine by Prisoners and Staff in Spanish Prisons. Vaccines (Basel) 2023; 11:1547. [PMID: 37896950 PMCID: PMC10610590 DOI: 10.3390/vaccines11101547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2023] [Revised: 09/23/2023] [Accepted: 09/27/2023] [Indexed: 10/29/2023] Open
Abstract
The COVID-19 vaccination of prisoners and prison staff represents a public health intervention to reduce the impact of the pandemic in conglomerate settings. In Spanish prisons, the road map of the Ministry of Health was followed to protect the population at risk. We conducted a cross-sectional study to assess the acceptance of COVID-19 vaccination by prisoners and prison staff in a prison in Alicante, Spain. We analyzed data obtained through a standardized, self-administered, and anonymous questionnaire; 1016 prisoners and 288 prison staff responded to the survey. The majority of inmates and staff reported no history of symptomatic COVID-19, 90.15% and 91.66%, respectively. Respondents reported that 88.72% agreed to be vaccinated and 89.64% would recommend the vaccine to others. Approximately 89% believe that the benefit of getting vaccinated against COVID-19 is greater than the risk, and 70.55% reported that vaccination should be mandatory for inmates and staff to participate in some activities. The acceptance of COVID-19 vaccination among prisoners and prison staff is high in a Provincial Prison in Spain. Elevated acceptance of COVID-19 vaccination in prisons is a major factor in public health intervention and vaccine equity.
Collapse
Affiliation(s)
| | - Sorina Madalina Sferle
- Instituto Universitario de Matemática Multidisciplinar, Universitat Politècnica de València, Camino de Vera, s/n, 46022 Valencia, Spain;
| | - Carlos Franco-Paredes
- Department of Microbiology, Immunology and Pathology, Children’s Hospital of Mexico Federico Gomez, Dr. Márquez 162, Ciudad de Mexico 06720, Mexico;
| | - José Tuells
- Department of Community Nursing, Preventive Medicine and Public Health and History of Science, University of Alicante, San Vicente del Raspeig, 03690 Alicante, Spain;
| |
Collapse
|
8
|
Moazen B, Agbaria N, Ismail N, Mazzilli S, Klankwarth UB, Amaya A, Rosello A, D'Arcy J, Plugge E, Stöver H, Tavoschi L. Interventions to increase vaccine uptake among people who live and work in prisons: A global multistage scoping review. JOURNAL OF COMMUNITY PSYCHOLOGY 2023. [PMID: 37462954 DOI: 10.1002/jcop.23077] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/05/2023] [Accepted: 07/08/2023] [Indexed: 08/03/2023]
Abstract
The objective of this study is to examine interventions implemented to increase vaccine uptake among people who live and work in prisons around the world. Peer-reviewed and gray literature databases were searched systematically to identify relevant information published from 2012 to 2022. Publications were evaluated by two researchers independently and underwent quality assessment through established tools. Of the 11,281 publications identified through peer-reviewed (2607) and gray literature (8674) search, 17 met the inclusion criteria. In light of limited data, the identified interventions were categorized into two categories of educational and organizational interventions, and are discussed in the text. The lack of availability of vaccination services and interventions to increase vaccine uptake among people who live and work in prisons, worldwide, is a serious public health concern. These interventions reported in this review can be adapted and adopted to mitigate the burden of infectious diseases among people who live and work in prisons.
Collapse
Affiliation(s)
- Babak Moazen
- Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany
- Department of Health and Social Work, Frankfurt University of Applied Sciences, Frankfurt/Main, Germany
| | - Nisreen Agbaria
- Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany
- Department of Health and Social Work, Frankfurt University of Applied Sciences, Frankfurt/Main, Germany
| | - Nasrul Ismail
- School for Policy Studies, University of Bristol, Bristol, UK
| | - Sara Mazzilli
- Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
| | - Ulla-Britt Klankwarth
- Department of Health and Social Work, Frankfurt University of Applied Sciences, Frankfurt/Main, Germany
| | - Arianna Amaya
- Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany
| | | | | | - Emma Plugge
- UK Health Security Agency, London, UK
- Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, UK
| | - Heino Stöver
- Department of Health and Social Work, Frankfurt University of Applied Sciences, Frankfurt/Main, Germany
| | - Lara Tavoschi
- Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
| |
Collapse
|
9
|
Lind ML, Kennedy BS, Nieto MD, Houde AJ, Sosensky P, Borg R, Cummings DAT, Ko AI, Richeson RP. Covid-19 vaccine acceptance among individuals incarcerated in Connecticut state jails. HEALTH & JUSTICE 2023; 11:16. [PMID: 36913159 PMCID: PMC10009345 DOI: 10.1186/s40352-023-00216-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Accepted: 02/21/2023] [Indexed: 06/18/2023]
Abstract
BACKGROUND Vaccine hesitancy is common among incarcerated populations and, despite vaccination programs, vaccine acceptance within residents remains low, especially within jails. With the goal of assessing the Connecticut DOC's COVID-19 vaccine program within jails we examined if residents of DOC operated jails were more likely to become vaccinated following incarceration than in the community. Specifically, we conducted a retrospective cohort analysis among people who spent at least one night in a DOC-operated jail between February 2 and November 8, 2021, and were eligible for vaccination at the time of incarceration (intake). We compared the vaccination rates before and after incarceration using an age-adjusted survival analysis with a time-varying exposure of incarceration and an outcome of vaccination. RESULTS During the study period, 3,716 people spent at least one night in jail and were eligible for vaccination at intake. Of these residents, 136 were vaccinated prior to incarceration, 2,265 had a recorded vaccine offer, and 479 were vaccinated while incarcerated. The age-adjusted hazard of vaccination following incarceration was significantly higher than prior to incarceration (12.5; 95% Confidence Intervals: 10.2-15.3). CONCLUSIONS We found that residents were more likely to become vaccinated in jail than in the community. Though these findings highlight the utility of vaccination programs within jails, the low level of vaccination in this population speaks to the need for additional program development within jails and the community.
Collapse
Affiliation(s)
- Margaret L. Lind
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, 60 College Street, New Haven, CT 06510 USA
| | - Byron S. Kennedy
- Connecticut Department of Correction, 24 Wolcott Hill Rd, Wethersfield, CT 06109 USA
| | - Murilo Dorion Nieto
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, 60 College Street, New Haven, CT 06510 USA
| | - Amy J. Houde
- Connecticut Department of Correction, 24 Wolcott Hill Rd, Wethersfield, CT 06109 USA
| | - Peri Sosensky
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, 60 College Street, New Haven, CT 06510 USA
| | - Ryan Borg
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, 60 College Street, New Haven, CT 06510 USA
| | - Derek A. T. Cummings
- Department of Biology, University of Florida, 214 Bartram Hall, Gainesville, FL 32611 USA
- Emerging Pathogens Institute, University of Florida, 2055 Mowry Rd, Gainesville, FL 32610 USA
| | - Albert I. Ko
- Connecticut Department of Correction, 24 Wolcott Hill Rd, Wethersfield, CT 06109 USA
- Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, BA Brazil
| | - Robert P. Richeson
- Connecticut Department of Correction, 24 Wolcott Hill Rd, Wethersfield, CT 06109 USA
| |
Collapse
|
10
|
Education increases COVID-19 vaccine uptake among people in Canadian federal prisons in a prospective randomized controlled trial: The EDUCATE study. Vaccine 2023; 41:1419-1425. [PMID: 36697314 PMCID: PMC9868384 DOI: 10.1016/j.vaccine.2023.01.040] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2022] [Revised: 01/13/2023] [Accepted: 01/17/2023] [Indexed: 01/25/2023]
Abstract
Education is key to behavioural adoption and acceptability of health interventions. We evaluated the impact of an educational intervention administered 1:1 to individuals incarcerated in four Canadian federal prisons on COVID-19 vaccine uptake. Eligible individuals (those who had refused all COVID-19 vaccines) were randomized 2:1 to receive the educational intervention or not (control group); those who received the intervention completed questionnaires assessing COVID-19 vaccine-related knowledge, attitudes, and beliefs pre- and post-educational intervention. The primary and secondary outcome measures were COVID-19 vaccine uptake and vaccine confidence, respectively. Between May 3 and September 9, 2022, 202 participants were randomized to receive the intervention, of whom 127 (63 %) agreed to participate. Participants who were randomized to the intervention had higher COVID-19 vaccine uptake vs. the control group (5 % vs 1 %, p = 0.046). COVID-19 vaccine-related knowledge, attitudes, and beliefs improved post-intervention. Education increases COVID-19 vaccine uptake and confidence among people in Canadian federal correctional facilities.
Collapse
|
11
|
Seroprevalence and factors associated with hepatitis B virus exposure in the incarcerated population from southern Brazil. PLoS One 2022; 17:e0278029. [PMID: 36413542 PMCID: PMC9681091 DOI: 10.1371/journal.pone.0278029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2022] [Accepted: 11/08/2022] [Indexed: 11/23/2022] Open
Abstract
Hepatitis B viral infection (HBV) in prisons poses serious public health challenges because it significantly contributes to the increase in both morbidity and mortality indicators worldwide. Research has shown high HBV prevalence among inmates when compared to the general population. In this study, we estimated the prevalence of HBV exposure and its risk factors among 1,132 inmates detained in high security institutions. A cross-sectional, epidemiological study was carried out in 11 male-only prisons in the State of Paraná, Brazil, between May 2015 to December 2016. HBV exposure was explored using a variety of methods, including HBsAg, anti-HBs, and total anti-HBc. Data were analyzed using univariate and multivariate techniques. The overall prevalence of HBV exposure was 11.9% (95% CI: 10.9-12.8), totaling 135 individuals. In the multivariate analyses, risk factors that remained statistically significant were related to the penitentiary location (Francisco Beltrão; OR = 5.59; 95% CI: 3.32-9.42), age (over 30 years; OR = 5.78; 95% CI: 3.58-9.34), undergoing tattooing procedures in prison (OR = 1.64; 95% CI: 1.03-2.60), self-reported sexual activities with a known drug user (OR = 1.67; 95% CI: 1.12-2.48) and having a history of previous history of hepatitis B or C infection (OR = 2.62; 95% CI: 1.48-4.64). The findings indicate that public policies-including vaccination, early diagnosis, harm reduction strategies, and adequate treatment-should be designed and delivered in the same way for both the incarcerated and the general population in order to reduce the prevalence of HBV and its associated consequences.
Collapse
|
12
|
Romanchuk K, Linthwaite B, Cox J, Park H, Dussault C, Basta NE, Varsaneux O, Worthington J, Lebouché B, MacDonald SE, Ismail SJ, Kronfli N. Determinants of SARS-CoV-2 vaccine willingness among people incarcerated in 3 Canadian federal prisons: a cross-sectional study. CMAJ Open 2022; 10:E922-E929. [PMID: 36280247 PMCID: PMC9640165 DOI: 10.9778/cmajo.20210248] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
BACKGROUND Maximizing uptake of SARS-CoV-2 vaccines among people in prison is essential in mitigating future outbreaks. We aimed to determine factors associated with willingness to receive SARS-CoV-2 vaccination before vaccine availability. METHODS We chose 3 Canadian federal prisons based on their low uptake of influenza vaccines in 2019-2020. Participants completed a self-administered questionnaire on knowledge, attitude and beliefs toward vaccines. The primary outcome was participant willingness to receive a SARS-CoV-2 vaccine, measured using a 5-point Likert scale to the question, "If a safe and effective COVID-19 vaccine becomes available in prison, how likely are you to get vaccinated?" We calculated the association of independent variables (age, ethnicity, chronic health conditions, 2019-2020 influenza vaccine uptake and prison security level), identified a priori, with vaccine willingness using logistic regression and crude and adjusted odds ratios (ORs) with 95% confidence intervals (CIs). RESULTS We recruited 240 participants from Mar. 31 to Apr. 19, 2021 (median age 46 years; 19.2% female, 25.8% Indigenous). Of these, 178 (74.2%) were very willing to receive a SARS-CoV-2 vaccine. Participants who received the 2019-2020 influenza vaccine (adjusted OR 5.20, 95% CI 2.43-12.00) had higher odds of vaccine willingness than those who did not; those who self-identified as Indigenous (adjusted OR 0.27, 95% CI 0.11-0.60) and in medium- or maximum-security prisons (adjusted OR 0.36, 95% CI 0.12-0.92) had lower odds of vaccine willingness than those who identified as white or those in minimum-security prisons, respectively. INTERPRETATION Most participants were very willing to receive vaccination against SARS-CoV-2 before vaccine roll-out. Vaccine promotion campaigns should target groups with low vaccine willingness (i.e., those who have declined influenza vaccine, identify as Indigenous or reside in high-security prisons).
Collapse
Affiliation(s)
- Kathryn Romanchuk
- Centre for Outcomes Research and Evaluation (Romanchuk, Linthwaite, Cox, Park, Dussault, Lebouché, Kronfli), Research Institute of the McGill University Health Centre; Department of Epidemiology, Biostatistics and Occupational Health (Cox, Basta, Kronfli), School of Population and Global Health, McGill University; Department of Medicine (Cox, Lebouché, Kronfli), Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, Montréal, Que.; Correctional Service Canada (Varsaneux, Worthington), Ottawa, Ont.; Department of Family Medicine (Lebouché), McGill University, Montréal, Que.; Faculty of Nursing (MacDonald), University of Alberta; School of Public Health (MacDonald), University of Alberta, Edmonton, Alta.; Division of Immunization Programs and Pandemic Preparedness (Ismail), Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada and Metro City Medical Clinic, Ottawa, Ont
| | - Blake Linthwaite
- Centre for Outcomes Research and Evaluation (Romanchuk, Linthwaite, Cox, Park, Dussault, Lebouché, Kronfli), Research Institute of the McGill University Health Centre; Department of Epidemiology, Biostatistics and Occupational Health (Cox, Basta, Kronfli), School of Population and Global Health, McGill University; Department of Medicine (Cox, Lebouché, Kronfli), Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, Montréal, Que.; Correctional Service Canada (Varsaneux, Worthington), Ottawa, Ont.; Department of Family Medicine (Lebouché), McGill University, Montréal, Que.; Faculty of Nursing (MacDonald), University of Alberta; School of Public Health (MacDonald), University of Alberta, Edmonton, Alta.; Division of Immunization Programs and Pandemic Preparedness (Ismail), Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada and Metro City Medical Clinic, Ottawa, Ont
| | - Joseph Cox
- Centre for Outcomes Research and Evaluation (Romanchuk, Linthwaite, Cox, Park, Dussault, Lebouché, Kronfli), Research Institute of the McGill University Health Centre; Department of Epidemiology, Biostatistics and Occupational Health (Cox, Basta, Kronfli), School of Population and Global Health, McGill University; Department of Medicine (Cox, Lebouché, Kronfli), Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, Montréal, Que.; Correctional Service Canada (Varsaneux, Worthington), Ottawa, Ont.; Department of Family Medicine (Lebouché), McGill University, Montréal, Que.; Faculty of Nursing (MacDonald), University of Alberta; School of Public Health (MacDonald), University of Alberta, Edmonton, Alta.; Division of Immunization Programs and Pandemic Preparedness (Ismail), Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada and Metro City Medical Clinic, Ottawa, Ont
| | - Hyejin Park
- Centre for Outcomes Research and Evaluation (Romanchuk, Linthwaite, Cox, Park, Dussault, Lebouché, Kronfli), Research Institute of the McGill University Health Centre; Department of Epidemiology, Biostatistics and Occupational Health (Cox, Basta, Kronfli), School of Population and Global Health, McGill University; Department of Medicine (Cox, Lebouché, Kronfli), Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, Montréal, Que.; Correctional Service Canada (Varsaneux, Worthington), Ottawa, Ont.; Department of Family Medicine (Lebouché), McGill University, Montréal, Que.; Faculty of Nursing (MacDonald), University of Alberta; School of Public Health (MacDonald), University of Alberta, Edmonton, Alta.; Division of Immunization Programs and Pandemic Preparedness (Ismail), Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada and Metro City Medical Clinic, Ottawa, Ont
| | - Camille Dussault
- Centre for Outcomes Research and Evaluation (Romanchuk, Linthwaite, Cox, Park, Dussault, Lebouché, Kronfli), Research Institute of the McGill University Health Centre; Department of Epidemiology, Biostatistics and Occupational Health (Cox, Basta, Kronfli), School of Population and Global Health, McGill University; Department of Medicine (Cox, Lebouché, Kronfli), Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, Montréal, Que.; Correctional Service Canada (Varsaneux, Worthington), Ottawa, Ont.; Department of Family Medicine (Lebouché), McGill University, Montréal, Que.; Faculty of Nursing (MacDonald), University of Alberta; School of Public Health (MacDonald), University of Alberta, Edmonton, Alta.; Division of Immunization Programs and Pandemic Preparedness (Ismail), Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada and Metro City Medical Clinic, Ottawa, Ont
| | - Nicole E Basta
- Centre for Outcomes Research and Evaluation (Romanchuk, Linthwaite, Cox, Park, Dussault, Lebouché, Kronfli), Research Institute of the McGill University Health Centre; Department of Epidemiology, Biostatistics and Occupational Health (Cox, Basta, Kronfli), School of Population and Global Health, McGill University; Department of Medicine (Cox, Lebouché, Kronfli), Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, Montréal, Que.; Correctional Service Canada (Varsaneux, Worthington), Ottawa, Ont.; Department of Family Medicine (Lebouché), McGill University, Montréal, Que.; Faculty of Nursing (MacDonald), University of Alberta; School of Public Health (MacDonald), University of Alberta, Edmonton, Alta.; Division of Immunization Programs and Pandemic Preparedness (Ismail), Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada and Metro City Medical Clinic, Ottawa, Ont
| | - Olivia Varsaneux
- Centre for Outcomes Research and Evaluation (Romanchuk, Linthwaite, Cox, Park, Dussault, Lebouché, Kronfli), Research Institute of the McGill University Health Centre; Department of Epidemiology, Biostatistics and Occupational Health (Cox, Basta, Kronfli), School of Population and Global Health, McGill University; Department of Medicine (Cox, Lebouché, Kronfli), Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, Montréal, Que.; Correctional Service Canada (Varsaneux, Worthington), Ottawa, Ont.; Department of Family Medicine (Lebouché), McGill University, Montréal, Que.; Faculty of Nursing (MacDonald), University of Alberta; School of Public Health (MacDonald), University of Alberta, Edmonton, Alta.; Division of Immunization Programs and Pandemic Preparedness (Ismail), Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada and Metro City Medical Clinic, Ottawa, Ont
| | - James Worthington
- Centre for Outcomes Research and Evaluation (Romanchuk, Linthwaite, Cox, Park, Dussault, Lebouché, Kronfli), Research Institute of the McGill University Health Centre; Department of Epidemiology, Biostatistics and Occupational Health (Cox, Basta, Kronfli), School of Population and Global Health, McGill University; Department of Medicine (Cox, Lebouché, Kronfli), Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, Montréal, Que.; Correctional Service Canada (Varsaneux, Worthington), Ottawa, Ont.; Department of Family Medicine (Lebouché), McGill University, Montréal, Que.; Faculty of Nursing (MacDonald), University of Alberta; School of Public Health (MacDonald), University of Alberta, Edmonton, Alta.; Division of Immunization Programs and Pandemic Preparedness (Ismail), Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada and Metro City Medical Clinic, Ottawa, Ont
| | - Bertrand Lebouché
- Centre for Outcomes Research and Evaluation (Romanchuk, Linthwaite, Cox, Park, Dussault, Lebouché, Kronfli), Research Institute of the McGill University Health Centre; Department of Epidemiology, Biostatistics and Occupational Health (Cox, Basta, Kronfli), School of Population and Global Health, McGill University; Department of Medicine (Cox, Lebouché, Kronfli), Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, Montréal, Que.; Correctional Service Canada (Varsaneux, Worthington), Ottawa, Ont.; Department of Family Medicine (Lebouché), McGill University, Montréal, Que.; Faculty of Nursing (MacDonald), University of Alberta; School of Public Health (MacDonald), University of Alberta, Edmonton, Alta.; Division of Immunization Programs and Pandemic Preparedness (Ismail), Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada and Metro City Medical Clinic, Ottawa, Ont
| | - Shannon E MacDonald
- Centre for Outcomes Research and Evaluation (Romanchuk, Linthwaite, Cox, Park, Dussault, Lebouché, Kronfli), Research Institute of the McGill University Health Centre; Department of Epidemiology, Biostatistics and Occupational Health (Cox, Basta, Kronfli), School of Population and Global Health, McGill University; Department of Medicine (Cox, Lebouché, Kronfli), Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, Montréal, Que.; Correctional Service Canada (Varsaneux, Worthington), Ottawa, Ont.; Department of Family Medicine (Lebouché), McGill University, Montréal, Que.; Faculty of Nursing (MacDonald), University of Alberta; School of Public Health (MacDonald), University of Alberta, Edmonton, Alta.; Division of Immunization Programs and Pandemic Preparedness (Ismail), Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada and Metro City Medical Clinic, Ottawa, Ont
| | - Shainoor J Ismail
- Centre for Outcomes Research and Evaluation (Romanchuk, Linthwaite, Cox, Park, Dussault, Lebouché, Kronfli), Research Institute of the McGill University Health Centre; Department of Epidemiology, Biostatistics and Occupational Health (Cox, Basta, Kronfli), School of Population and Global Health, McGill University; Department of Medicine (Cox, Lebouché, Kronfli), Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, Montréal, Que.; Correctional Service Canada (Varsaneux, Worthington), Ottawa, Ont.; Department of Family Medicine (Lebouché), McGill University, Montréal, Que.; Faculty of Nursing (MacDonald), University of Alberta; School of Public Health (MacDonald), University of Alberta, Edmonton, Alta.; Division of Immunization Programs and Pandemic Preparedness (Ismail), Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada and Metro City Medical Clinic, Ottawa, Ont
| | - Nadine Kronfli
- Centre for Outcomes Research and Evaluation (Romanchuk, Linthwaite, Cox, Park, Dussault, Lebouché, Kronfli), Research Institute of the McGill University Health Centre; Department of Epidemiology, Biostatistics and Occupational Health (Cox, Basta, Kronfli), School of Population and Global Health, McGill University; Department of Medicine (Cox, Lebouché, Kronfli), Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, Montréal, Que.; Correctional Service Canada (Varsaneux, Worthington), Ottawa, Ont.; Department of Family Medicine (Lebouché), McGill University, Montréal, Que.; Faculty of Nursing (MacDonald), University of Alberta; School of Public Health (MacDonald), University of Alberta, Edmonton, Alta.; Division of Immunization Programs and Pandemic Preparedness (Ismail), Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada and Metro City Medical Clinic, Ottawa, Ont.
| |
Collapse
|
13
|
Khorasani S, Zubiago J, Carreiro J, Guardado R, Wurcel AG. Influenza Vaccination in Massachusetts Jails: A Mixed-Methods Analysis. Public Health Rep 2022; 137:936-943. [PMID: 34524903 PMCID: PMC9379841 DOI: 10.1177/00333549211041659] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2021] [Revised: 07/12/2021] [Accepted: 07/26/2021] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVES Influenza infects millions of people each year and contributes to tens of thousands of deaths annually despite the availability of vaccines. People most at risk of influenza complications are disproportionately represented in people incarcerated in US prisons and jails. The objectives of this study were to survey health administrators in Massachusetts county jails about institutional influenza vaccine policies and practices and estimate influenza vaccination rates in Massachusetts jails from 2013 to 2020. METHODS In April 2020, we administered surveys to the health services administrators in Massachusetts' 14 county jails to gather information about influenza vaccination policies and delivery practices. To calculate influenza vaccination rates for each facility, we obtained data on influenza vaccine orders from the Massachusetts Department of Public Health for each county in Massachusetts for influenza seasons 2013-2020. We calculated summary statistics for each reporting facility and each year, conducted a Kruskal-Wallis analysis to compare vaccination rates between years, and used a linear regression model to identify predictors of vaccination rates. RESULTS Influenza vaccination rates in Massachusetts jails ranged from 1.9% to 11.8%. We found no significant differences in vaccination rates between years. Influenza vaccine ordering and delivery practices varied by jail, and respondents had high levels of confidence in influenza policies and vaccine delivery practices. CONCLUSIONS Influenza vaccination rates in Massachusetts jails are low, and delivery practices in jails vary. Lack of influenza vaccinations in jails is a gap in health care that needs to be prioritized, especially considering the current COVID-19 pandemic. Further investigations for effective and equitable vaccination in this population should involve people who are incarcerated and people who make influenza vaccine policies in jails.
Collapse
Affiliation(s)
| | - Julia Zubiago
- Division of Geographic Medicine and Infectious Diseases,
Department of Medicine, Tufts Medical Center, Boston, MA, USA
| | - Jac Carreiro
- Tufts University School of Medicine, Boston, MA, USA
| | - Rubeen Guardado
- Division of Geographic Medicine and Infectious Diseases,
Department of Medicine, Tufts Medical Center, Boston, MA, USA
| | - Alysse G. Wurcel
- Tufts University School of Medicine, Boston, MA, USA
- Division of Geographic Medicine and Infectious Diseases,
Department of Medicine, Tufts Medical Center, Boston, MA, USA
| |
Collapse
|
14
|
Di Giuseppe G, Folcarelli L, Lanzano R, Napolitano F, Pavia M. HPV Vaccination and Cervical Cancer Screening: Assessing Awareness, Attitudes, and Adherence in Detained Women. Vaccines (Basel) 2022; 10:vaccines10081280. [PMID: 36016168 PMCID: PMC9416201 DOI: 10.3390/vaccines10081280] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2022] [Revised: 08/03/2022] [Accepted: 08/05/2022] [Indexed: 12/04/2022] Open
Abstract
Background: This study assessed awareness, attitudes, and uptake of human papillomavirus (HPV) vaccination and cervical cancer screening in detained women. Methods: The cross-sectional study was conducted from April to June 2022 in four women prisons in Italy. Results: 41.1% of participants recognized HPV infection as an sexually transmitted diseases (STD), 36.4% identified cervical, and 16.8% oral cancer as an HPV-associated disease. Overall, 70% had never heard of HPV vaccination, and 45.8% believed it is effective to prevent cervical cancer. Among the age-eligible women for HPV vaccination, none reported to have undergone it, nor had talked about it with a physician in the previous year. Only 13.5% declared to have ever undergone cervical cancer screening, and adherence was significantly higher in those who were involved in a working activity in prison, who were aware that HPV infection is an STD and that can cause cervical and oral cancer, and who were older at their first sexual intercourse. Conclusion: These findings documented an extremely low awareness of HPV infection and an unsatisfactory adherence to prevention through HPV vaccination and cervical cancer screening. There is a need for evidence-based interventions for incarcerated women to promote participation in HPV vaccination and cervical cancer screening programs as routine activities.
Collapse
|
15
|
Ceesay A, Lemoine M, Cohen D, Chemin I, Ndow G. Clinical utility of the 'Determine HBsAg' Point-of-Care Test for Diagnosis of Hepatitis B Surface Antigen in Africa. Expert Rev Mol Diagn 2022; 22:497-505. [PMID: 35574686 DOI: 10.1080/14737159.2022.2076595] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
INTRODUCTION Chronic infection with hepatitis B virus (HBV) is a leading cause of morbidity and death, especially in sub-Saharan Africa (sSSA), where approximately 60 million adults are infected. More than 90% of these patients are unaware of their HBV status. AREAS COVERED Scaling-up of HBV screening programs in SSA are essential to increase diagnosis, linkage to care and access to treatment, and will ultimately reduce HBV disease burden to achieve WHO hepatitis elimination targets. Such scale up will rely on inexpensive rapid point-of-care (POC) tests, especially in remote areas where gold standard serological assays are not routinely available. This review discusses the diagnostic performance and clinical utility of the Determine™ (Abbott, USA) hepatitis B surface Antigen (HBsAg) POC test for improving HBV screening in SSA, in light with others available HBsAg rapid tests. EXPERT OPINION The Determine™ HBsAg POC test has demonstrated relatively good diagnostic accuracy at the low cost, in the African field and laboratory and should be used for large scale mass screening of HBV infection in Africa.
Collapse
Affiliation(s)
- Amie Ceesay
- Medical Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine, Fajara, P.O. Box 273, Banjul, The Gambia.,Cancer Research Center, INSERM U1052, Lyon, France
| | - Maud Lemoine
- Department of Metabolism, Digestion and Reproduction, Division of Digestive Diseases, Imperial College London. St. Mary's Hospital campus, London, UK
| | - Damien Cohen
- Cancer Research Center, INSERM U1052, Lyon, France
| | | | - Gibril Ndow
- Medical Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine, Fajara, P.O. Box 273, Banjul, The Gambia.,Department of Metabolism, Digestion and Reproduction, Division of Digestive Diseases, Imperial College London. St. Mary's Hospital campus, London, UK
| |
Collapse
|
16
|
COVID-19 Vaccination Uptake and Related Determinants in Detained Subjects in Italy. Vaccines (Basel) 2022; 10:vaccines10050673. [PMID: 35632429 PMCID: PMC9146091 DOI: 10.3390/vaccines10050673] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2022] [Revised: 04/15/2022] [Accepted: 04/20/2022] [Indexed: 12/26/2022] Open
Abstract
Background: This study explored the extent of COVID-19 vaccination coverage and investigated drivers and barriers to COVID-19 vaccine uptake among people in prison. Methods: This cross-sectional study was conducted from July to October 2021 among 517 detained people in the Campania region of South Italy. Results: In total, 47.1% of participants expressed a high concern about contracting COVID-19 after vaccination, whereas 60.6% and 53.8% of respondents reported a positive attitude towards usefulness and safety of COVID-19 vaccines, respectively. Adherence to the active offer of COVID-19 vaccination involved 89.7% of detained subjects. COVID-19 vaccination uptake was significantly higher in females, and in those who reported influenza vaccination uptake, had received information about COVID-19 vaccination from media and newspapers, did not express need of additional information about COVID-19 vaccine, believed that COVID-19 vaccine is safe, were involved in working activities in the prison, and had a high school or university degree. Conclusions: These findings showed a high self-reported COVID-19 vaccination coverage in detained subjects, supporting the effectiveness of the strategy aimed at giving priority to COVID-19 vaccinations in prisons. Further efforts are needed to contrast the hesitancy of those who refused vaccination to increase their confidence about usefulness and safety of COVID-19 vaccines.
Collapse
|
17
|
Lessard D, Ortiz-Paredes D, Park H, Varsaneux O, Worthington J, Basta NE, MacDonald SE, Lebouché B, Cox J, Ismail SJ, Kronfli N. Barriers and facilitators to COVID-19 vaccine acceptability among people incarcerated in Canadian federal prisons: A qualitative study. Vaccine X 2022; 10:100150. [PMID: 35243324 PMCID: PMC8883835 DOI: 10.1016/j.jvacx.2022.100150] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2021] [Revised: 01/24/2022] [Accepted: 02/16/2022] [Indexed: 12/16/2022] Open
Abstract
INTRODUCTION Canadian correctional institutions have been prioritized for COVID-19 vaccination given the multiple outbreaks that have occurred since the start of the pandemic. Given historically low vaccine uptake, we aimed to explore barriers and facilitators to COVID-19 vaccination acceptability among people incarcerated in federal prisons. METHODS Three federal prisons in Quebec, Ontario, and British Columbia (Canada) were chosen based on previously low influenza vaccine uptake among those incarcerated. Using a qualitative design, semi-structured interviews were conducted with a diverse sample (gender, age, and ethnicity) of incarcerated people. An inductive-deductive analysis of audio-recorded interview transcripts was conducted to identify and categorize barriers and facilitators within the Theoretical Domains Framework (TDF). RESULTS From March 22-29, 2021, a total of 15 participants (n = 5 per site; n = 5 women; median age = 43 years) were interviewed, including five First Nations people and six people from other minority groups. Eleven (73%) expressed a desire to receive a COVID-19 vaccine, including two who previously refused influenza vaccination. We identified five thematic barriers across three TDF domains: social influences (receiving strict recommendations, believing in conspiracies to harm), beliefs about consequences (believing that infection control measures will not be fully lifted, concerns with vaccine-related side effects), and knowledge (lack of vaccine-specific information), and eight thematic facilitators across five TDF domains: environmental context and resources (perceiving correctional employees as sources of outbreaks, perceiving challenges to prevention measures), social influences (receiving recommendations from trusted individuals), beliefs about consequences (seeking individual and collective protection, believing in a collective "return to normal", believing in individual privileges), knowledge (reassurance about vaccine outcomes), and emotions (having experienced COVID-19-related stress). CONCLUSIONS Lack of information and misinformation were important barriers to COVID-19 vaccine acceptability among people incarcerated in Canadian federal prisons. This suggests that educational interventions, delivered by trusted health care providers, may improve COVID-19 vaccine uptake going forward.
Collapse
Affiliation(s)
- David Lessard
- Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Canada.,Canadian Institutes of Health Research Strategy for Patient-Oriented Research Mentorship Chair in Innovative Clinical Trial in HIV, Research Institute of the McGill University Health Centre, Canada
| | - David Ortiz-Paredes
- Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Canada
| | - Hyejin Park
- Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Canada
| | | | | | - Nicole E Basta
- Department of Epidemiology, Biostatistics and Occupational Health, School of Population and Global Health, McGill University, Canada
| | - Shannon E MacDonald
- Faculty of Nursing, University of Alberta, Canada.,School of Public Health, University of Alberta, Canada
| | - Bertrand Lebouché
- Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Canada.,Canadian Institutes of Health Research Strategy for Patient-Oriented Research Mentorship Chair in Innovative Clinical Trial in HIV, Research Institute of the McGill University Health Centre, Canada.,Department of Family Medicine, McGill University, Canada.,Department of Medicine, Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, Canada
| | - Joseph Cox
- Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Canada.,Department of Epidemiology, Biostatistics and Occupational Health, School of Population and Global Health, McGill University, Canada.,Department of Medicine, Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, Canada
| | - Shainoor J Ismail
- Division of Immunization Programs and Pandemic Preparedness, Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada and Metro City Medical Clinic, Canada
| | - Nadine Kronfli
- Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Canada.,Department of Epidemiology, Biostatistics and Occupational Health, School of Population and Global Health, McGill University, Canada.,Department of Medicine, Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, Canada
| |
Collapse
|
18
|
Ortiz-Paredes D, Varsaneux O, Worthington J, Park H, MacDonald SE, Basta NE, Lebouché B, Cox J, Ismail SJ, Kronfli N. Reasons for COVID-19 vaccine refusal among people incarcerated in Canadian federal prisons. PLoS One 2022; 17:e0264145. [PMID: 35263350 PMCID: PMC8906611 DOI: 10.1371/journal.pone.0264145] [Citation(s) in RCA: 23] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2021] [Accepted: 02/03/2022] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Vaccine uptake rates have been historically low in correctional settings. To better understand vaccine hesitancy in these high-risk settings, we explored reasons for COVID-19 vaccine refusal among people in federal prisons. METHODS Three maximum security all-male federal prisons in British Columbia, Alberta, and Ontario (Canada) were chosen, representing prisons with the highest proportions of COVID-19 vaccine refusal. Using a qualitative descriptive design and purposive sampling, individual semi-structured interviews were conducted with incarcerated people who had previously refused at least one COVID-19 vaccine until data saturation was achieved. An inductive-deductive thematic analysis of audio-recorded interview transcripts was conducted using the Conceptual Model of Vaccine Hesitancy. RESULTS Between May 19-July 8, 2021, 14 participants were interviewed (median age: 30 years; n = 7 Indigenous, n = 4 visible minority, n = 3 White). Individual-, interpersonal-, and system-level factors were identified. Three were particularly relevant to the correctional setting: 1) Risk perception: participants perceived that they were at lower risk of COVID-19 due to restricted visits and interactions; 2) Health care services in prison: participants reported feeling "punished" and stigmatized due to strict COVID-19 restrictions, and failed to identify personal benefits of vaccination due to the lack of incentives; 3) Universal distrust: participants expressed distrust in prison employees, including health care providers. INTERPRETATION Reasons for vaccine refusal among people in prison are multifaceted. Educational interventions could seek to address COVID-19 risk misconceptions in prison settings. However, impact may be limited if trust is not fostered and if incentives are not considered in vaccine promotion.
Collapse
Affiliation(s)
- David Ortiz-Paredes
- Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
| | | | | | - Hyejin Park
- Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
| | - Shannon E. MacDonald
- Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada
- School of Public Health, University of Alberta, Edmonton, Alberta, Canada
| | - Nicole E. Basta
- Department of Epidemiology, Biostatistics and Occupational Health, School of Population and Global Health, McGill University, Montreal, Quebec, Canada
| | - Bertrand Lebouché
- Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
- Department of Family Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada
- Division of Infectious Diseases and Chronic Viral Illness Service, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada
| | - Joseph Cox
- Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
- Department of Epidemiology, Biostatistics and Occupational Health, School of Population and Global Health, McGill University, Montreal, Quebec, Canada
- Division of Infectious Diseases and Chronic Viral Illness Service, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada
| | - Shainoor J. Ismail
- Division of Immunization Programs and Pandemic Preparedness, Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, Ontario, Canada
- Metro City Medical Clinic, Edmonton, Alberta, Canada
| | - Nadine Kronfli
- Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
- Department of Epidemiology, Biostatistics and Occupational Health, School of Population and Global Health, McGill University, Montreal, Quebec, Canada
- Division of Infectious Diseases and Chronic Viral Illness Service, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada
- * E-mail:
| |
Collapse
|
19
|
Di Giuseppe G, Pelullo CP, Lanzano R, Napolitano F, Pavia M. Knowledge, attitudes, and behavior of incarcerated people regarding COVID-19 and related vaccination: a survey in Italy. Sci Rep 2022; 12:960. [PMID: 35046470 PMCID: PMC8770777 DOI: 10.1038/s41598-022-04919-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2021] [Accepted: 12/24/2021] [Indexed: 12/18/2022] Open
Abstract
The cross-sectional study assessed knowledge, attitudes, and preventive practices toward COVID-19 disease of incarcerated people. A total of 685 subjects were surveyed. 94% were aware that respiratory droplets are involved in the transmission of COVID-19, and 77.2% that patients with chronic conditions are at risk of a more severe disease. Overall, 92.7% of respondents considered COVID-19 a more severe disease compared to influenza, and 85.4% believed that COVID-19 could cause serious consequences in their institution. Only 22.6% were self-confident about their ability to protect themselves from SARS-CoV-2 infection. This attitude was significantly higher in those who were involved in working activities in the institution, who did not report at least one common symptom compatible with COVID-19 in the previous 3 months, who did not show generalized anxiety symptoms, and did not need additional information. 63.9% of incarcerated people expressed willingness to receive COVID-19 vaccination. Older subjects, who knew that a COVID-19 vaccination is available, believed that COVID-19 is more serious than influenza, and were self-confident about their ability to protect themselves from SARS-CoV-2 infection, were significantly more willing to undergo COVID-19 vaccination. Public health response to COVID-19 in prisons should address vaccine hesitancy to increase vaccine confidence among incarcerated people.
Collapse
Affiliation(s)
- Gabriella Di Giuseppe
- Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Via Luciano Armanni, 5, 80138, Naples, Italy
| | - Concetta P Pelullo
- Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Via Luciano Armanni, 5, 80138, Naples, Italy
| | - Raffaele Lanzano
- Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Via Luciano Armanni, 5, 80138, Naples, Italy
| | - Francesco Napolitano
- Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Via Luciano Armanni, 5, 80138, Naples, Italy
| | - Maria Pavia
- Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Via Luciano Armanni, 5, 80138, Naples, Italy.
| |
Collapse
|
20
|
Ramaswamy M, Satterwhite CL, Lipnicky A, Emerson A, Griffin P, Ash D, Ault K. Recommendations for Delivering COVID-19 Vaccine in Jails: Evidence from Kansas, Iowa, Nebraska, and Missouri. Am J Public Health 2021; 111:1035-1039. [PMID: 33950714 DOI: 10.2105/ajph.2021.306218] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
We report on data we collected from a 2018 survey examining jails' human papillomavirus virus vaccine delivery capacity and on a secondary analysis we conducted to describe factors similarly associated with delivery planning for the COVID-19 vaccine. We provide recommendations for delivering the COVID-19 vaccine in jails, based on evidence from Kansas, Iowa, Nebraska, and Missouri. Our key finding is that jails have limited staff to implement vaccination and will require collaboration between jail administrators, jail medical staff, and local health departments.
Collapse
Affiliation(s)
- Megha Ramaswamy
- Megha Ramaswamy, Ashlyn Lipnicky, and Kevin Ault are with the University of Kansas Medical Center, Kansas City. Catherine L. Satterwhite is with the Office of the Assistant Secretary for Health, US Department of Health and Human Services, Kansas City, MO. Amanda Emerson is with the School of Nursing and Health Studies, University of Missouri-Kansas City. Phil Griffin is with the Bureau of Disease Control and Prevention, Kansas Department of Health and Environment, Topeka. Donald Ash is with the Wyandotte County, Kansas Sheriff's Office, Kansas City, KS
| | - Catherine L Satterwhite
- Megha Ramaswamy, Ashlyn Lipnicky, and Kevin Ault are with the University of Kansas Medical Center, Kansas City. Catherine L. Satterwhite is with the Office of the Assistant Secretary for Health, US Department of Health and Human Services, Kansas City, MO. Amanda Emerson is with the School of Nursing and Health Studies, University of Missouri-Kansas City. Phil Griffin is with the Bureau of Disease Control and Prevention, Kansas Department of Health and Environment, Topeka. Donald Ash is with the Wyandotte County, Kansas Sheriff's Office, Kansas City, KS
| | - Ashlyn Lipnicky
- Megha Ramaswamy, Ashlyn Lipnicky, and Kevin Ault are with the University of Kansas Medical Center, Kansas City. Catherine L. Satterwhite is with the Office of the Assistant Secretary for Health, US Department of Health and Human Services, Kansas City, MO. Amanda Emerson is with the School of Nursing and Health Studies, University of Missouri-Kansas City. Phil Griffin is with the Bureau of Disease Control and Prevention, Kansas Department of Health and Environment, Topeka. Donald Ash is with the Wyandotte County, Kansas Sheriff's Office, Kansas City, KS
| | - Amanda Emerson
- Megha Ramaswamy, Ashlyn Lipnicky, and Kevin Ault are with the University of Kansas Medical Center, Kansas City. Catherine L. Satterwhite is with the Office of the Assistant Secretary for Health, US Department of Health and Human Services, Kansas City, MO. Amanda Emerson is with the School of Nursing and Health Studies, University of Missouri-Kansas City. Phil Griffin is with the Bureau of Disease Control and Prevention, Kansas Department of Health and Environment, Topeka. Donald Ash is with the Wyandotte County, Kansas Sheriff's Office, Kansas City, KS
| | - Phil Griffin
- Megha Ramaswamy, Ashlyn Lipnicky, and Kevin Ault are with the University of Kansas Medical Center, Kansas City. Catherine L. Satterwhite is with the Office of the Assistant Secretary for Health, US Department of Health and Human Services, Kansas City, MO. Amanda Emerson is with the School of Nursing and Health Studies, University of Missouri-Kansas City. Phil Griffin is with the Bureau of Disease Control and Prevention, Kansas Department of Health and Environment, Topeka. Donald Ash is with the Wyandotte County, Kansas Sheriff's Office, Kansas City, KS
| | - Donald Ash
- Megha Ramaswamy, Ashlyn Lipnicky, and Kevin Ault are with the University of Kansas Medical Center, Kansas City. Catherine L. Satterwhite is with the Office of the Assistant Secretary for Health, US Department of Health and Human Services, Kansas City, MO. Amanda Emerson is with the School of Nursing and Health Studies, University of Missouri-Kansas City. Phil Griffin is with the Bureau of Disease Control and Prevention, Kansas Department of Health and Environment, Topeka. Donald Ash is with the Wyandotte County, Kansas Sheriff's Office, Kansas City, KS
| | - Kevin Ault
- Megha Ramaswamy, Ashlyn Lipnicky, and Kevin Ault are with the University of Kansas Medical Center, Kansas City. Catherine L. Satterwhite is with the Office of the Assistant Secretary for Health, US Department of Health and Human Services, Kansas City, MO. Amanda Emerson is with the School of Nursing and Health Studies, University of Missouri-Kansas City. Phil Griffin is with the Bureau of Disease Control and Prevention, Kansas Department of Health and Environment, Topeka. Donald Ash is with the Wyandotte County, Kansas Sheriff's Office, Kansas City, KS
| |
Collapse
|
21
|
Stern MF, Piasecki AM, Strick LB, Rajeshwar P, Tyagi E, Dolovich S, Patel PR, Fukunaga R, Furukawa NW. Willingness to Receive a COVID-19 Vaccination Among Incarcerated or Detained Persons in Correctional and Detention Facilities - Four States, September-December 2020. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT 2021; 70:473-477. [PMID: 33793457 PMCID: PMC8022882 DOI: 10.15585/mmwr.mm7013a3] [Citation(s) in RCA: 52] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|